The Nuria Millan Testing Repack report concludes that the re-packaged product [meets/does not meet] the required standards. The testing process identified [number] defects, which have been documented and prioritized for resolution. Recommendations have been made for improvements to the product and testing process.
Releasing the "repack" to a community once testing is passed. nuria millan testing repack
As of 2025, the bottleneck for the process is volume. Millan is one woman with one lab. The demand is global. Waiting times can stretch to 6–8 weeks. Emerging competitors (such as Janoshik Analytical) have tried to replicate the model, but Millan remains the "OG" standard due to her tenure. The Nuria Millan Testing Repack report concludes that
| Phase | Activity | Pass/Fail Criteria | |-------|----------|---------------------| | 1 | Visual inspection of original units | No cracks, leaks, or tampering | | 2 | Functional test (if applicable) | Operates as spec | | 3 | Removal of old packaging / labels | No residue or damage | | 4 | Placement into new packaging | Correct orientation, padding | | 5 | Sealing & labeling | Barcode scan passes, seal intact | | 6 | Final audit sample (e.g., AQL level II) | ≤1.5% defect rate | Releasing the "repack" to a community once testing is passed
Over 18 months, zero positive sterility tests, zero endotoxin failures, and a 60% reduction in waste (because they could extend BUDs from 7 to 14 days with stability data). The hospital’s compliance score during the next FDA inspection rose from “needs improvement” to “exemplary.”